DaVita Inc.
DVA
NYSE·Healthcare·Medical - Care Facilities·Mkt cap $11.8B
$183.99
▲ +1.28%
P/E
40.98
Mkt Cap
$11.8B
52-Wk Range
$101.00–$247.49
52-Week Range
$101.00 - $247.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 36.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive nationwide dialysis center network
- Comprehensive kidney care ecosystem
- Advanced clinical research capabilities
- Integrated care management expertise
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising chronic kidney disease prevalence
Value
Undervalued - trading well below Healthcare Facilities peers
Momentum
Stable
-4.2% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DVA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
AUG 4, 2026
Reported EPS of $4.02 vs $3.88 consensus (+3.6% surprise). Revenue of $3.6B vs $3.5B expected (+1.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+3.6%
Revenue trend · last 8Q
—
+5%
+5%
+6%
+5%
+10%
+6%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.3B
$3.3B
$3.2B
$3.4B
$3.4B
$3.6B
$3.4B
$3.6B
Margins · last 8Q
Gross
-30.2%
Operating
16.3%
Profit
7.5%
Wall Street consensus
5 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 7, 2026
vs Industry
How DVA stacks vs Medical - Care Facilities
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related